Cyto Pulse Sciences Announces Approval for Phase I/II DNA Vaccine Study
Posted on: Monday, 13 October 2008, 09:00 CDT
Cyto Pulse Sciences has received approval from the Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with recurring prostate cancer.
The trial will investigate the safety of a xenogenic DNA vaccine delivered by the Derma Vax intradermal electroporation system.
The vaccine, which encodes prostate specific antigen (PSA) from a Rhesus Macaque, was developed jointly by Cyto Pulse and the Karolinska Institute and has been licensed to Cyto Pulse. The clinical trial will be conducted at the department of oncology at Uppsala University Hospital.
Richard Walters, Cyto Pulse's CEO, said: "This is a significant step forward for our DNA vaccine delivery system, Derma Vax. The Derma Vax delivery system is designed to be safe, effective and with an emphasis on maximum comfort for the patient. We are hopeful that the treatment will prove to be effective."
Source: Datamonitor
Related Articles
- Pulse Systems Announces New $8.5 Million Credit Facility
- Pulse Systems Receives Dual Certification Under ISO 13485:2003 and ISO 9001:2008
- New Delivery System Hikes Vaccine Response
- Stratus Technologies and Pulse Systems, Inc. Partner to Serve EHR and Practice Management Market
- Inovio Biomedical Redirects Strategic Emphasis Toward DNA Vaccines and DNA Delivery
- Cyto Pulse Sciences, Inc. Awarded $2 Million By NIH for DNA Vaccine Delivery System Commercialization
- Geron Licenses MaxCyte Cell Loading Technology for Use in Closed-System Cancer Vaccine Manufacturing
- Cyto Pulse Sciences, Inc. Awarded Grant By Maryland Technology Development Corporation for a Smallpox DNA Vaccine Delivery Project
- Cyto Pulse Sciences Inc. Working With USAMRIID on Marburg Vaccine Delivery Development
 |
 |
User Comments (0)
RSS Feeds